medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»medalphabet-145Research ArticleСтатьиПалбоциклиб (Ибранса®) - новые возможности гормонотерапии люминального HER2-отрицательного метастатического рака молочной железыPalbociclib (Ibransa®): new possibilities of hormone therapy for luminal her2-negative metastatic breast cancerКоролеваИ. А.KorolevaI. A.noemail@neicon.ruКоппМ. В.KoppM. V.noemail@neicon.ruЧУООВО «Медицинский университет „РЕАВИЗ“»РоссияSamara Medical University ‘REAVIZ’Russian Federation201725052017116Диагностика и онкотерапия611Copyright © Королева И.А., Копп М.В., 20172017Королева И.А., Копп М.В.Koroleva I.A., Kopp M.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/145

Гормонотерапия является основным методом лечения эстроген-рецептор-позитивного (РЭ+) HER2-негативного метастатического рака молочной железы (мРМЖ). Циклинзависимые киназы 4 и 6 (CDK4/6) являются регуляторами перехода клеток из фазы G1 в фазу S клеточного цикла. Активность CDK4/6 увеличивается в клетках ER+ рака молочной железы. CDK4/6 являются ключевыми мишенями сигнального пути от РЭ. Палбоциклиб - первый пероральный ингибитор CDK4/6. На сегодняшний день стали доступны результаты двух крупных исследований III фазы PALOMA-2 и PALOMA-3, включающих пациентов РЭ+ HER 2-негативного мРМЖ. Палбоциклиб в комбинации с летрозолом значительно увеличил выживаемость без прогрессирования (ВБП) по сравнению с летрозолом в первой линии терапии мРМЖ. Добавление палбоциклиба к фулвестрану увеличило ВБП по сравнению с фулвестрантом у женщин с мРМЖ во второй линии терапии.

Hormonal therapy is the main treatment for estrogen receptor positive (ER+) HER 2-negative metastatic breast cancer. Cyclin-dependent kinases 4 and 6 (CDK4/6) are regulators of cell transition from G1 phase to S phase of the cell cycle. The activity of CDK4/6 is increased in the cells of the ER+ breast cancer. CDK4/6 are key targets of signal pathways from the estrogen receptors. Palbociclib is a first-in-class oral inhibitor of CDK4/6. The article presents results of two large randomized phase III trials PALOMA-2 and PALOMA-3, including patients with ER+ HER 2-negative advanced breast cancer. Palbociclib in combination with letrozole significantly improved progression-free survival (PFS) compared with letrozole alone as first-line treatment of advanced breast cancer. Adding palbociclib to fulvestrant results in longer PFS than fulvestrant alone in women with advanced breast cancer as second-line treatment.

метастатический рак молочной железыгормонотерапиялетрозолфулвестрантпалбоциклибmetastatic breast cancerhormonal therapyletrozolefulvestrantpalbociclibReferencesКаприн А. Д., Старинский В. В., Петрова Г. В. (ред.). Состояние онкологической помощи населению России в 2015 году.- М.: МНИОИ им. П. А. Герцена филиал ФГБУ «НМИРЦ» Минздрава России, 2016. - 236 с.Каприн А. Д., Старинский В. В., Петрова Г. В. (ред.). Состояние онкологической помощи населению России в 2015 году.- М.: МНИОИ им. П. А. Герцена филиал ФГБУ «НМИРЦ» Минздрава России, 2016. - 236 с.Saad E., Katz A., Machado K., Buyse M. Post-progression survival (PPS) and overall survival (OS) according to treatment type in contemporary phase III trials in advanced breast cancer (ABC). SABCS2009; abstr. 5116.Saad E., Katz A., Machado K., Buyse M. Post-progression survival (PPS) and overall survival (OS) according to treatment type in contemporary phase III trials in advanced breast cancer (ABC). SABCS2009; abstr. 5116.Dawood S., Broglio K., Gonzalez-Angulo A. M. et al. Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. J. Clin. Oncol. 2008; 26: 4891-4898.Dawood S., Broglio K., Gonzalez-Angulo A. M. et al. Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. J. Clin. Oncol. 2008; 26: 4891-4898.Стенина М. Б., Жукова Л. Г., Королева И. А. и соавт. Практические рекомендации по лекарственному лечению инвазивного рака молочной железы // Злокачественные опухоли. - 2016. - № 4. Спецвыпуск 2. - С. 97-122.Стенина М. Б., Жукова Л. Г., Королева И. А. и соавт. Практические рекомендации по лекарственному лечению инвазивного рака молочной железы // Злокачественные опухоли. - 2016. - № 4. Спецвыпуск 2. - С. 97-122.Cleator S. J., Ahamed E., Coombes R. C., Palmieri C. A 2009 update on the treatment of patients with hormone receptor-positive breast cancer // Clin. Breast Cancer. - 2009/ - № 9 / - Suppl. 1. Р. 6-17.Cleator S. J., Ahamed E., Coombes R. C., Palmieri C. A 2009 update on the treatment of patients with hormone receptor-positive breast cancer // Clin. Breast Cancer. - 2009/ - № 9 / - Suppl. 1. Р. 6-17.Ingle J. N., Krook J. E., Green S. J. et al. Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer // J. Clin. Oncol. - 1986. - № 4. - P. 178-185.Ingle J. N., Krook J. E., Green S. J. et al. Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer // J. Clin. Oncol. - 1986. - № 4. - P. 178-185.Veronesi U., Pizzocaro G., Rossi A. Oophorectomy for advanced carcinoma of the breast // Surg. Gynecol. Obstet. - 1975. - T. 141. - P. 569-570.Veronesi U., Pizzocaro G., Rossi A. Oophorectomy for advanced carcinoma of the breast // Surg. Gynecol. Obstet. - 1975. - T. 141. - P. 569-570.Conte C. C., Nemoto T., Rosner D. et al. Therapeutic oophorectomy in metastatic breast cancer // Cancer. - 1989. - T. 64. - P. 150-153.Conte C. C., Nemoto T., Rosner D. et al. Therapeutic oophorectomy in metastatic breast cancer // Cancer. - 1989. - T. 64. - P. 150-153.Oriana S., Bohm S., Baeli A. et al. Clinical response and survival according to estrogen receptor levels after bilateral ovariectomy in advanced breast cancer // Eur. J. Surg. Oncol. - 1989. T. 15. - P. 39-42.Oriana S., Bohm S., Baeli A. et al. Clinical response and survival according to estrogen receptor levels after bilateral ovariectomy in advanced breast cancer // Eur. J. Surg. Oncol. - 1989. T. 15. - P. 39-42.Wilcken N., Hornbuckle J., Ghersi D. Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst. Rev. 2003; CD002747.Wilcken N., Hornbuckle J., Ghersi D. Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst. Rev. 2003; CD002747.Australian and New Zealand Breast Cancer Trial Groups, Clinical Oncological Society of Australia. A randomised trial in post-menopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination // J. Clin. Oncol. - 1986. - № 4. - P. 186-193.Australian and New Zealand Breast Cancer Trial Groups, Clinical Oncological Society of Australia. A randomised trial in post-menopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination // J. Clin. Oncol. - 1986. - № 4. - P. 186-193.Mehta R. S., Barlow W. E., Albain K. S., et al. Combination anastrozole and fulvestrant in metastatic breast cancer // N. Engl. J. Med. - 2012. - № 367. - P. 435-444.Mehta R. S., Barlow W. E., Albain K. S., et al. Combination anastrozole and fulvestrant in metastatic breast cancer // N. Engl. J. Med. - 2012. - № 367. - P. 435-444.Fry D. W., Harvey P. J., Keller P. R., et al. Specific Inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts // Molecular Cancer Therapeutics. 2004. - № 3. - P. 1427-1437.Fry D. W., Harvey P. J., Keller P. R., et al. Specific Inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts // Molecular Cancer Therapeutics. 2004. - № 3. - P. 1427-1437.Finn R. S., Dering J., Conklin D. et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro // Breast Cancer Res. 2009. - № 11 (5). - P. 77.Finn R. S., Dering J., Conklin D. et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro // Breast Cancer Res. 2009. - № 11 (5). - P. 77.Finn R. S., Crown J. P., Lang I., et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozol versus letrozol alone as first-line treatment of oestrogen receptor-positive, HER 2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomized phase 2 study // Lancet Oncology. - 2015. - № 16. - P. 25-35.Finn R. S., Crown J. P., Lang I., et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozol versus letrozol alone as first-line treatment of oestrogen receptor-positive, HER 2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomized phase 2 study // Lancet Oncology. - 2015. - № 16. - P. 25-35.Finn R. S., Martin M., Jones S. E., et al. PALO-MA-2: primary results from a phase iii trial of palbociclib (p) with letrozole (l) compared with letrozole alone in postmenopausal women with er+/her2- advanced breast cancer (abc) // J. Clin. Oncol. - 2016. - № 34 (suppl.; abstr 507).Finn R. S., Martin M., Jones S. E., et al. PALO-MA-2: primary results from a phase iii trial of palbociclib (p) with letrozole (l) compared with letrozole alone in postmenopausal women with er+/her2- advanced breast cancer (abc) // J. Clin. Oncol. - 2016. - № 34 (suppl.; abstr 507).Turner N. C., Ro J., Andre F., et al. Palbociclib in hormone-receptor-positive advanced breast cancer // N. Engl. J. Med. - 2015. - № 373. - P. 209-219.Turner N. C., Ro J., Andre F., et al. Palbociclib in hormone-receptor-positive advanced breast cancer // N. Engl. J. Med. - 2015. - № 373. - P. 209-219.Cristofanilli M., Turner N. C., et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER 2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): fi nal analysis of the multicentre, double-blind, phase randomised controlled trial // Lancet Oncol. - 2016. - № 17 (4). - P. 425-439.Cristofanilli M., Turner N. C., et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER 2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): fi nal analysis of the multicentre, double-blind, phase randomised controlled trial // Lancet Oncol. - 2016. - № 17 (4). - P. 425-439.Loibl S., Turner N. C., Ro J., et al. Palbociclib (PAL) in combination with fulvestrant (F) in pre-/peri-menopausal (PreM) women with metastatic breast cancer (MBC) and prior progression on endocrine therapy - results from Paloma-3 // J. Clin. Oncol. - 2016. - № 34 (suppl.; abstr. 524).Loibl S., Turner N. C., Ro J., et al. Palbociclib (PAL) in combination with fulvestrant (F) in pre-/peri-menopausal (PreM) women with metastatic breast cancer (MBC) and prior progression on endocrine therapy - results from Paloma-3 // J. Clin. Oncol. - 2016. - № 34 (suppl.; abstr. 524).National Comprehensive Cancer: NCCN Clinical Practice Guidelines in Oncology. Breast Cancer 2.2016. https://www.nccn.org.National Comprehensive Cancer: NCCN Clinical Practice Guidelines in Oncology. Breast Cancer 2.2016. https://www.nccn.org.Rugo H. S., Rumle B., Macrae E. et al. Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline // J. Clin. Oncol. - 2016. - 34, № 25. - Р. 3069-3103.Rugo H. S., Rumle B., Macrae E. et al. Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline // J. Clin. Oncol. - 2016. - 34, № 25. - Р. 3069-3103.

The authors declare that there are no conflicts of interest present.